BRAF and melanoma: This study uncovers an essential interplay between the eIF4F translation initiation complex, which contributes to melanoma resistance, and the extracellular signal-regulated kinase (ERK) signaling pathway, the primary therapeutic target in melanomas with BRAF and NRAS mutations.